newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

Significant reduction in minimum purchase requirements 2026 manufacturing capacity expansion expected to result in further reductions in cost of goods Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that on